ES2368941T3 - Angiopep-1, compuestos relacionados y utilizaciones correspondientes. - Google Patents
Angiopep-1, compuestos relacionados y utilizaciones correspondientes. Download PDFInfo
- Publication number
- ES2368941T3 ES2368941T3 ES04700102T ES04700102T ES2368941T3 ES 2368941 T3 ES2368941 T3 ES 2368941T3 ES 04700102 T ES04700102 T ES 04700102T ES 04700102 T ES04700102 T ES 04700102T ES 2368941 T3 ES2368941 T3 ES 2368941T3
- Authority
- ES
- Spain
- Prior art keywords
- agent
- conjugate
- aprotinin
- carrier
- brain barrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 74
- 230000008499 blood brain barrier function Effects 0.000 claims abstract description 69
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 69
- 239000003814 drug Substances 0.000 claims abstract description 48
- 229960004405 aprotinin Drugs 0.000 claims description 81
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 70
- 108010039627 Aprotinin Proteins 0.000 claims description 69
- 230000031998 transcytosis Effects 0.000 claims description 46
- 210000004556 brain Anatomy 0.000 claims description 42
- 230000032258 transport Effects 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000012581 transferrin Substances 0.000 claims description 14
- 208000012902 Nervous system disease Diseases 0.000 claims description 13
- 208000025966 Neurological disease Diseases 0.000 claims description 12
- 102000004338 Transferrin Human genes 0.000 claims description 12
- 108090000901 Transferrin Proteins 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 229940126586 small molecule drug Drugs 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 31
- 238000000034 method Methods 0.000 abstract description 17
- 230000006872 improvement Effects 0.000 abstract description 6
- 238000012377 drug delivery Methods 0.000 abstract 2
- 238000002474 experimental method Methods 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 229960002685 biotin Drugs 0.000 description 20
- 239000011616 biotin Substances 0.000 description 20
- 230000035699 permeability Effects 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 210000003169 central nervous system Anatomy 0.000 description 16
- 230000004888 barrier function Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 230000002490 cerebral effect Effects 0.000 description 12
- 238000009826 distribution Methods 0.000 description 12
- 238000009825 accumulation Methods 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000001130 astrocyte Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000010874 in vitro model Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 208000015114 central nervous system disease Diseases 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 150000001615 biotins Chemical class 0.000 description 4
- 210000001043 capillary endothelial cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 108010075016 Ceruloplasmin Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000003788 cerebral perfusion Effects 0.000 description 3
- 238000009513 drug distribution Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- -1 coatings Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 108010045676 holotransferrin Proteins 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012881 co-culture medium Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43798603P | 2003-01-06 | 2003-01-06 | |
| US437986P | 2003-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2368941T3 true ES2368941T3 (es) | 2011-11-23 |
Family
ID=32713262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04700102T Expired - Lifetime ES2368941T3 (es) | 2003-01-06 | 2004-01-05 | Angiopep-1, compuestos relacionados y utilizaciones correspondientes. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9221867B2 (enExample) |
| EP (2) | EP1583562B1 (enExample) |
| JP (2) | JP4903036B2 (enExample) |
| CN (2) | CN1747747B (enExample) |
| AT (1) | ATE512674T1 (enExample) |
| AU (2) | AU2004203682B2 (enExample) |
| BR (1) | BRPI0406647A (enExample) |
| CA (1) | CA2516056C (enExample) |
| CY (1) | CY1111844T1 (enExample) |
| DK (1) | DK1583562T3 (enExample) |
| ES (1) | ES2368941T3 (enExample) |
| MX (1) | MXPA05007322A (enExample) |
| PT (1) | PT1583562E (enExample) |
| SI (1) | SI1583562T1 (enExample) |
| WO (1) | WO2004060403A2 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1583562T3 (da) * | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, beslægtede forbindelser og anvendelser deraf |
| EP1841455A1 (en) | 2005-01-24 | 2007-10-10 | Amgen Inc. | Humanized anti-amyloid antibody |
| PT2360258E (pt) * | 2005-02-18 | 2015-01-13 | Angiochem Inc | Moléculas para transportar um composto através da barreira hematoencefálica |
| US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| DK2233156T3 (da) * | 2005-07-15 | 2013-08-05 | Angiochem Inc | Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater |
| JP4945766B2 (ja) * | 2006-01-24 | 2012-06-06 | 国立大学法人 鹿児島大学 | 脳神経細胞への薬物の標的化剤 |
| US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US8487072B2 (en) | 2006-10-19 | 2013-07-16 | Angiochem Inc. | Compounds for stimulating P-glycoprotein function and uses thereof |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| PL2164866T3 (pl) * | 2007-05-29 | 2014-10-31 | Angiochem Inc | Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek |
| JP5844971B2 (ja) * | 2007-05-29 | 2016-01-20 | アンジオケム，インコーポレーテッド | コンジュゲートされた物質を組織に送達するためのアプロチニン様ポリペプチド |
| WO2009085200A2 (en) | 2007-12-21 | 2009-07-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| BRPI0910557A2 (pt) | 2008-04-18 | 2015-09-29 | Angiochem Inc | composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. |
| US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
| US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
| US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
| US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
| US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
| EP2280741A4 (en) | 2008-04-29 | 2012-06-13 | Virginia Tech Intell Prop | IRREVERSIBLE ELECTROPORATION FOR THE PRODUCTION OF TISSUE OBJECTS |
| US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
| US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
| US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
| US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
| RU2531591C2 (ru) * | 2008-10-15 | 2014-10-20 | Ангиокем Инк. | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
| RU2011118056A (ru) | 2008-10-15 | 2012-11-27 | Ангиокем Инк. | Конъюгаты агонистов glp-1 и их применение |
| CN102307904A (zh) | 2008-12-05 | 2012-01-04 | 安吉奥开米公司 | 神经降压素或神经降压素类似物的缀合物及其用途 |
| AU2009327267A1 (en) | 2008-12-17 | 2011-07-14 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| DE102009006228A1 (de) | 2009-01-27 | 2010-07-29 | Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh | Liposomale Zusammensetzung zur Behandlung von Hirnmetastasen |
| US8632534B2 (en) | 2009-04-03 | 2014-01-21 | Angiodynamics, Inc. | Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD) |
| US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
| US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| CA2759129C (en) | 2009-04-20 | 2018-12-11 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| WO2010138919A2 (en) | 2009-05-28 | 2010-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
| US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
| US9161988B2 (en) | 2009-07-02 | 2015-10-20 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| EP3144670B1 (en) * | 2009-10-30 | 2018-10-03 | Keio University | Anticancer agent sensitivity-determining marker |
| CA2803646A1 (en) * | 2010-07-02 | 2012-01-05 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| WO2012051433A2 (en) | 2010-10-13 | 2012-04-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
| WO2012088149A2 (en) | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
| EP2682401A4 (en) * | 2011-02-02 | 2015-06-03 | Microbial Chem Res Found | FOR OBTAINING THE BLOOD-BRAIN-DISABLED MEDICAMENT OUTPUT MATERIAL, PEPTIDE THEREOF AND USE THEREOF |
| US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
| US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
| CA2881602A1 (en) | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
| US9888956B2 (en) | 2013-01-22 | 2018-02-13 | Angiodynamics, Inc. | Integrated pump and generator device and method of use |
| AU2014243816B2 (en) * | 2013-03-13 | 2019-01-31 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| SG10201902074UA (en) | 2013-10-04 | 2019-04-29 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| CN113616656B (zh) | 2014-03-19 | 2023-02-17 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| JP6594901B2 (ja) | 2014-05-12 | 2019-10-23 | バージニア テック インテレクチュアル プロパティース インコーポレイテッド | パルス電界を使用した細胞の細胞内効果の選択的調節 |
| US12114911B2 (en) | 2014-08-28 | 2024-10-15 | Angiodynamics, Inc. | System and method for ablating a tissue site by electroporation with real-time pulse monitoring |
| CN105585614B (zh) * | 2014-10-24 | 2019-06-07 | 中国科学技术大学 | 用于淀粉样蛋白显像的血管肽及其衍生物 |
| EP3222291B1 (en) * | 2014-10-24 | 2020-08-19 | University of Science and Technology of China | Angiopeptin conjugates for amyloid protein targeting |
| US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
| DK3307326T3 (da) | 2015-06-15 | 2020-10-19 | Angiochem Inc | Fremgangsmåder til behandling af leptomeningeal karcinomatose |
| US11207461B2 (en) | 2015-07-30 | 2021-12-28 | Anoop U. R | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier |
| AU2016322552B2 (en) | 2015-09-14 | 2021-03-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| CN106188308B (zh) * | 2016-07-12 | 2019-08-20 | 西安医学院 | 一种跨血脑屏障蛋白转运体及制备方法和应用 |
| US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
| WO2018226992A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
| EP3668886A2 (en) | 2017-08-18 | 2020-06-24 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| CN111867573A (zh) | 2018-01-29 | 2020-10-30 | 科诺斯治疗学公司 | 硼替佐米的瘤内递送 |
| US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
| US12390262B2 (en) | 2018-03-13 | 2025-08-19 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| US10842755B2 (en) | 2018-03-23 | 2020-11-24 | University Of South Carolina | Nanoparticles for brain targeted drug delivery |
| US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
| US12214189B2 (en) | 2019-07-24 | 2025-02-04 | Virginia Tech Intellectual Properties, Inc. | Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies |
| CA3128035A1 (en) | 2020-08-13 | 2022-02-13 | Bioasis Technologies, Inc. | Combination therapies for delivery across the blood brain barrier |
| US12485279B2 (en) | 2020-11-25 | 2025-12-02 | Virginia Tech Intellectual Properties, Inc. | Methods for modulating temporal infrastructure of pulsed electric fields |
Family Cites Families (184)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| EP0260306A4 (en) | 1986-03-13 | 1990-09-26 | Biotechnology Pty Ltd | Method of assay of inhibin |
| US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4904768A (en) * | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
| GB2208511A (en) * | 1987-08-07 | 1989-04-05 | Bayer Ag | Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology |
| US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| US5632990A (en) | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
| US5258499A (en) * | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US5028697A (en) * | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5948634A (en) * | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| DE3912638A1 (de) | 1989-04-18 | 1990-10-31 | Bayer Ag | Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel |
| US5126249A (en) * | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US6475781B1 (en) | 1990-05-17 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Trans-dominant suppressor genes for oligomeric proteins |
| GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
| US5714167A (en) * | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| JPH07108232B2 (ja) * | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | ペプチド又は蛋白質の製造方法 |
| US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
| US5955444A (en) * | 1991-08-09 | 1999-09-21 | Massachusetts Institute Of Technology | Method of inhibiting abnormal tau hyper phosphorylation in a cell |
| US5627270A (en) * | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
| US5204354A (en) * | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
| GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| JPH08504568A (ja) * | 1992-09-25 | 1996-05-21 | コルバス・インターナショナル、インコーポレイテッド | ウシ膵トリプシン阻害因子から誘導される因子ＶＩＩａ−組織因子複合体の阻害因子 |
| EP0599303A3 (en) * | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
| WO1994019692A1 (en) * | 1993-02-18 | 1994-09-01 | The General Hospital Corporation | Alzheimer's disease therapeutics |
| WO1996031531A2 (en) * | 1995-04-04 | 1996-10-10 | Advanced Bioconcept, Inc. | Fluorescent peptides |
| AU5854096A (en) | 1995-05-08 | 1996-11-29 | Scios Inc. | Kunitz type protease inhibitors |
| ZA963619B (en) * | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| WO1996039183A1 (en) | 1995-05-31 | 1996-12-12 | Fred Hutchinson Cancer Research Center | Compositions and methods for targeted delivery of effector molecules |
| US5780265A (en) * | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| JP3469584B2 (ja) * | 1996-03-11 | 2003-11-25 | バイエル コーポレイション | ヒト ビクニン |
| WO1997040160A1 (en) | 1996-04-24 | 1997-10-30 | Rijksuniversiteit Te Groningen | A prokaryotic protein having functional and structural homology with the human p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein |
| AU729643B2 (en) | 1996-05-01 | 2001-02-08 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
| DE19636889A1 (de) * | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| EP0932390A1 (en) | 1996-10-11 | 1999-08-04 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| DE69838544T2 (de) | 1997-03-04 | 2008-07-24 | Savient Pharmaceuticals, Inc. | Isolierung von gewebespezifischen peptidliganden und ihre verwendung zur ausrichtung von pharmazeutika auf zielorgane |
| US6126965A (en) * | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| GB9705903D0 (en) * | 1997-03-21 | 1997-05-07 | Elliott Gillian D | VP22 Proteins and uses thereof |
| ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| US6391305B1 (en) * | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US6093692A (en) * | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
| WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| ES2274621T3 (es) | 1998-03-12 | 2007-05-16 | Georgetown University | Peptidos que contienen una secuencia de reconocimiento del colesterol y usos de los mismos. |
| US5981564A (en) | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
| GB9814527D0 (en) | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
| JP4808846B2 (ja) * | 1999-02-24 | 2011-11-02 | ザ ユーエイビー リサーチ ファンデイション | 癌の標的付けられた治療のためのタキサン誘導体 |
| US6138375A (en) * | 1999-03-01 | 2000-10-31 | Gala Industries, Inc. | Support ring for pellet dryer screen |
| US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| PT1214292E (pt) * | 1999-09-24 | 2007-09-14 | Genentech Inc | Derivados de tirosina |
| US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
| DE19953696A1 (de) * | 1999-11-09 | 2001-05-10 | Alexander Cherkasky | Selektive proteolytische Synzyme (SPS) |
| DE19953966A1 (de) * | 1999-11-09 | 2001-05-10 | Leica Microsystems | Verfahren und Vorrichtung zur Dickenmessung an transparenten Schichten |
| GB2360453B (en) | 2000-01-05 | 2004-09-01 | Univ Cardiff | Treatment of skin conditions |
| US20020086384A1 (en) * | 2000-03-14 | 2002-07-04 | Zurit Levine | Splice variants of oncogenes |
| CA2355334A1 (en) | 2000-10-16 | 2002-04-16 | Procyon Biopharma Inc. | Pharmaceutical preparations and methods for inhibiting tumors |
| CA2421042C (en) | 2000-10-20 | 2011-07-05 | Abbott Laboratories | The use of tiagabine for treatment of diabetic neuropathy and migraine |
| WO2002043765A2 (en) | 2000-11-28 | 2002-06-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| EP1383492A4 (en) | 2001-03-23 | 2008-12-24 | Napro Biotherapeutics Inc | MOLECULAR CONJUGATES FOR USE IN CANCER THERAPY |
| DK2322631T3 (en) | 2001-04-19 | 2015-01-12 | Scripps Research Inst | Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar |
| WO2003102583A1 (en) | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
| WO2003009815A2 (en) | 2001-07-25 | 2003-02-06 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
| US7192921B2 (en) * | 2001-11-08 | 2007-03-20 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
| EP1472351B1 (en) * | 2002-02-07 | 2007-06-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Amino acid sequences capable of facilitating penetration across a biological barrier |
| ATE441661T1 (de) * | 2002-03-29 | 2009-09-15 | Creagene Inc | Zytoplasmatische transduktionspeptide und deren verwendungen |
| US6881829B2 (en) * | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| JP2005537244A (ja) * | 2002-06-28 | 2005-12-08 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法 |
| US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| US20040102369A1 (en) * | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US7319090B2 (en) * | 2002-11-27 | 2008-01-15 | University Of North Carolina At Chapel Hill | Methods of treating cerebral ischemia |
| DK1583562T3 (da) * | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, beslægtede forbindelser og anvendelser deraf |
| US20040162284A1 (en) * | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
| EP1615655B1 (en) | 2003-04-08 | 2012-02-22 | Biotempt B.V. | Use of compositions for mucosal and oral administration comprising hcg fragments |
| ES2366185T3 (es) | 2003-04-11 | 2011-10-18 | Institut Pasteur | Vacunas de péptidos sintéticas para vih: el epítopo de cbd como un inmunógeno eficaz para provocar anticuerpos ampliamente neutralizantes contra el vih. |
| AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| JP5624256B2 (ja) | 2003-06-20 | 2014-11-12 | ラプター・ファーマシューティカル・インコーポレイテッド | 脳および他の組織への治療化合物の送達 |
| KR20060036476A (ko) | 2003-08-08 | 2006-04-28 | 가부시키가이샤 티슈 타겟팅 쟈판 | 뇌 이동 활성을 가지는 폴리펩티드 및 그 이용 |
| JP2007512001A (ja) | 2003-08-28 | 2007-05-17 | バイオレクシス ファーマシューティカル コーポレイション | Ｅｐｏミメティックペプチドおよび融合タンパク質 |
| US20050058702A1 (en) * | 2003-09-17 | 2005-03-17 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
| US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
| US7208174B2 (en) * | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
| JP2008507280A (ja) * | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
| DE602005015994D1 (de) * | 2004-09-29 | 2009-09-24 | Childrens Memorial Hospital | siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN |
| US9002652B1 (en) * | 2005-01-27 | 2015-04-07 | Institute For Systems Biology | Methods for identifying and using organ-specific proteins in blood |
| PT2360258E (pt) * | 2005-02-18 | 2015-01-13 | Angiochem Inc | Moléculas para transportar um composto através da barreira hematoencefálica |
| US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| CN103285395A (zh) | 2005-02-18 | 2013-09-11 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| JP5137814B2 (ja) | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート |
| WO2006124737A2 (en) * | 2005-05-12 | 2006-11-23 | Tapestry Pharmaceuticals, Inc. | Molecular constructs suitable for targeted conjugates |
| WO2006138343A2 (en) | 2005-06-14 | 2006-12-28 | Raptor Pharmaceutical Inc. | Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof |
| DK2233156T3 (da) | 2005-07-15 | 2013-08-05 | Angiochem Inc | Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater |
| BRPI0615562A2 (pt) * | 2005-07-19 | 2010-01-26 | Univ Illinois | agentes de transporte para atravessamento da barreira sangue-cérebro e entrada nas células cancerìgenas do cérebro e métodos para o seu uso |
| GB0517092D0 (en) | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
| CA2621694A1 (en) | 2005-09-08 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Pharmaceutical compositions for delivery of ribonucleic acid to a cell |
| US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
| US8142781B2 (en) | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| US20070197460A1 (en) * | 2005-11-01 | 2007-08-23 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
| US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
| US8290433B2 (en) * | 2007-11-14 | 2012-10-16 | Blaze Mobile, Inc. | Method and system for securing transactions made through a mobile communication device |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| SI2402754T2 (sl) | 2006-03-06 | 2023-09-29 | Amunix Operating Inc. | Nestrukturirani rekombinantni polimeri in njihove uporabe |
| US7477504B1 (en) | 2006-03-13 | 2009-01-13 | C.P.D. Technologies, Inc. | Versatile stun glove |
| DE602007003703D1 (de) | 2006-03-30 | 2010-01-21 | Glaxo Group Ltd | Gegen amyloid-beta peptid gerichtete antikörper |
| WO2008100328A2 (en) * | 2006-07-13 | 2008-08-21 | Burnham Institute For Medical Research | METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32 |
| EP2046826B1 (en) | 2006-07-24 | 2011-09-14 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
| JP2010503710A (ja) | 2006-09-18 | 2010-02-04 | ラプトール ファーマシューティカル インコーポレイテッド | 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置 |
| US8487072B2 (en) | 2006-10-19 | 2013-07-16 | Angiochem Inc. | Compounds for stimulating P-glycoprotein function and uses thereof |
| US9399675B2 (en) * | 2007-02-28 | 2016-07-26 | The Board Of Regents Of The University Of Oklahoma | Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration |
| KR20100015786A (ko) | 2007-03-21 | 2010-02-12 | 랩터 파마슈티컬 인코포레이티드 | 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드 |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| PL2164866T3 (pl) | 2007-05-29 | 2014-10-31 | Angiochem Inc | Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek |
| US8802631B2 (en) * | 2007-09-17 | 2014-08-12 | Ludwig Institute For Cancer Research Ltd. | Peptides and methods for the treatment of gliomas and other cancers |
| JP5697450B2 (ja) | 2007-10-02 | 2015-04-08 | マリーナ バイオテック，インコーポレイテッド | 核酸の送達のためのリポペプチド |
| WO2009070597A2 (en) | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
| EP2235175A4 (en) | 2007-12-20 | 2012-04-25 | Angiochem Inc | POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF |
| US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| CA2713872A1 (en) | 2008-02-21 | 2009-08-27 | Burnham Institute For Medical Research | Methods and compositions related to peptides and proteins with c-terminal elements |
| BRPI0910557A2 (pt) | 2008-04-18 | 2015-09-29 | Angiochem Inc | composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. |
| WO2010006239A2 (en) | 2008-07-10 | 2010-01-14 | The Board Of Trustees Of The University Of Illinois | Regulation of apoptosis by neural specific splice variants of ig20 |
| RU2011118056A (ru) | 2008-10-15 | 2012-11-27 | Ангиокем Инк. | Конъюгаты агонистов glp-1 и их применение |
| RU2531591C2 (ru) | 2008-10-15 | 2014-10-20 | Ангиокем Инк. | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
| RU2011125366A (ru) | 2008-12-05 | 2013-01-10 | Ангиочем Инк. | Конъюгаты терапевтических пептидов и их применение |
| MX2011005965A (es) | 2008-12-05 | 2011-09-01 | Angiochem Inc | Conjugados de leptina y de análogos de leptina y sus usos de los mismos. |
| CN102307904A (zh) * | 2008-12-05 | 2012-01-04 | 安吉奥开米公司 | 神经降压素或神经降压素类似物的缀合物及其用途 |
| AU2009327267A1 (en) | 2008-12-17 | 2011-07-14 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| CA2759129C (en) | 2009-04-20 | 2018-12-11 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| US20100284921A1 (en) | 2009-05-08 | 2010-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Targeted nanoparticles for intracellular cancer therapy |
| CN102497870A (zh) * | 2009-06-03 | 2012-06-13 | 戴瑟纳制药公司 | 肽-dicer底物试剂及其特异性抑制基因表达的方法 |
| CA2764777A1 (en) | 2009-06-11 | 2010-12-16 | Angiochem Inc. | Fusion proteins for delivery of gdnf and bdnf to the central nervous system |
| US9161988B2 (en) | 2009-07-02 | 2015-10-20 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| HRP20160136T1 (hr) | 2009-07-14 | 2016-03-11 | Mayo Foundation For Medical Education And Research | Peptidno posredovana ne-kovalentna isporuka aktivnih sredstava kroz krvno moždanu barijeru |
| WO2011041897A1 (en) | 2009-10-06 | 2011-04-14 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| US8530429B2 (en) * | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| EP2333074A1 (en) | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
| ES2661367T3 (es) | 2010-03-08 | 2018-03-28 | Sloan Kettering Institute For Cancer Research | Inhibidores de cinasa CDC7 y sus usos |
| EP2550285B1 (en) * | 2010-03-22 | 2017-07-19 | President and Fellows of Harvard College | Trioxacarcins and uses thereof |
| WO2011119608A1 (en) * | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
| US8986689B2 (en) * | 2010-04-14 | 2015-03-24 | National Research Council Of Canada | Compositions and methods for brain delivery of analgesic peptides |
| WO2011153642A1 (en) | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
| CA2803646A1 (en) | 2010-07-02 | 2012-01-05 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| US8218280B2 (en) | 2010-07-08 | 2012-07-10 | Schneider Electric USA, Inc. | Secondary thermal sensor for primary conductors |
| US20120156130A1 (en) * | 2010-08-06 | 2012-06-21 | Thore Hettmann | Use of her3 binding agents in prostate treatment |
| CN102406949B (zh) | 2010-09-21 | 2013-05-29 | 复旦大学 | 一种靶向示踪的多模式诊断纳米影像药物 |
| WO2012037687A1 (en) | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
| EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
| RU2013127625A (ru) | 2010-11-18 | 2014-12-27 | Зе Дженерал Хоспитал Корпорейшен | Новые композиции и применения антигипертензивных средств для терапии рака |
| CN102552928A (zh) | 2010-12-19 | 2012-07-11 | 复旦大学 | 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法 |
| NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| CN102614105A (zh) | 2011-01-28 | 2012-08-01 | 复旦大学 | 一种脑靶向载两性霉素b聚合物胶束给药系统 |
| US20130337051A1 (en) | 2011-03-01 | 2013-12-19 | To-Bbb Holding B.V. | Advanced active liposomal loading of poorly water-soluble substances |
| US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| EP2696898A4 (en) | 2011-04-07 | 2014-10-01 | Univ Emory | COMPOSITIONS WITH SACCHARIDE-BINDING PARTS AND PROCEDURE FOR TARGETED THERAPY |
| RU2013154422A (ru) | 2011-05-09 | 2015-06-20 | Институт Кимик Де Саррия | Полимерные наночастицы, предназначенные для доставки лекарственных средств |
| WO2013004716A1 (en) | 2011-07-04 | 2013-01-10 | Universität Basel | Peptide beads |
| TWI565709B (zh) * | 2011-07-19 | 2017-01-11 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
| EP2734520B1 (en) * | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX2014001662A (es) | 2011-08-11 | 2014-08-26 | Intellikine Llc | Polimeros inhibidores de cinasas. |
| RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
| US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| WO2013056096A1 (en) | 2011-10-13 | 2013-04-18 | Angiochem Inc. | Polypeptide-opioid conjugates and uses thereof |
| EA032088B1 (ru) | 2011-10-27 | 2019-04-30 | Массачусетс Инститьют Оф Текнолоджи | Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство |
| HK1201271A1 (en) | 2011-11-11 | 2015-08-28 | Intellikine, Llc | Kinase inhibitor polymorphs |
| EP2785838A4 (en) | 2011-12-01 | 2015-07-01 | Angiochem Inc | VECTORIZED LYSOSOMAL ENZYME COMPOUNDS |
| RU2014126482A (ru) | 2011-12-01 | 2016-01-27 | Ангиочем Инк. | Нацеленные соединения ферментов и их применение |
| HUE052136T2 (hu) * | 2011-12-13 | 2021-04-28 | Engeneic Molecular Delivery Pty Ltd | Bakteriális eredetû intakt minisejtek terápiás szerek agydaganatokba történõ bejuttatására |
| CA2859205A1 (en) | 2011-12-16 | 2013-06-20 | Massachusetts Institute Of Technology | Alpha-aminoamidine polymers and uses thereof |
| WO2013120107A1 (en) | 2012-02-09 | 2013-08-15 | University Of Rochester | Methods and compositions for treating a subject to inhibit hearing loss |
| US20150037281A1 (en) | 2012-03-02 | 2015-02-05 | Icahn School Of Medicine At Mount Sinai | Variants of prothymosin alpha and methods of using same |
| SI2833905T1 (en) | 2012-04-04 | 2018-08-31 | Halozyme, Inc. | Combination therapy with hyaluronidase and tumane-directed taxane |
| US9745334B2 (en) | 2012-04-26 | 2017-08-29 | Yale University | Cytotoxic-drug delivering molecules targeting HIV (CDM-Hs), cytotoxic activity against the human immunodeficiency virus and methods of use |
| CA2876525A1 (en) | 2012-06-15 | 2013-12-19 | Angiochem Inc. | Targeted iduromdase compounds |
-
2004
- 2004-01-05 DK DK04700102.9T patent/DK1583562T3/da active
- 2004-01-05 BR BR0406647-2A patent/BRPI0406647A/pt not_active Application Discontinuation
- 2004-01-05 AU AU2004203682A patent/AU2004203682B2/en not_active Ceased
- 2004-01-05 SI SI200431732T patent/SI1583562T1/sl unknown
- 2004-01-05 ES ES04700102T patent/ES2368941T3/es not_active Expired - Lifetime
- 2004-01-05 MX MXPA05007322A patent/MXPA05007322A/es active IP Right Grant
- 2004-01-05 EP EP04700102A patent/EP1583562B1/en not_active Expired - Lifetime
- 2004-01-05 JP JP2006500425A patent/JP4903036B2/ja not_active Expired - Fee Related
- 2004-01-05 EP EP10009847A patent/EP2260874A1/en not_active Withdrawn
- 2004-01-05 CN CN2004800035448A patent/CN1747747B/zh not_active Expired - Fee Related
- 2004-01-05 CN CN2012102486937A patent/CN102775472A/zh active Pending
- 2004-01-05 PT PT04700102T patent/PT1583562E/pt unknown
- 2004-01-05 WO PCT/CA2004/000011 patent/WO2004060403A2/en not_active Ceased
- 2004-01-05 AT AT04700102T patent/ATE512674T1/de active
- 2004-01-05 US US10/541,304 patent/US9221867B2/en active Active
- 2004-01-05 CA CA2516056A patent/CA2516056C/en not_active Expired - Lifetime
-
2009
- 2009-12-29 AU AU2009251223A patent/AU2009251223B2/en not_active Ceased
-
2011
- 2011-09-15 CY CY20111100889T patent/CY1111844T1/el unknown
- 2011-10-28 JP JP2011237203A patent/JP2012031197A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1583562B1 (en) | 2011-06-15 |
| SI1583562T1 (sl) | 2011-10-28 |
| CA2516056C (en) | 2012-05-29 |
| JP4903036B2 (ja) | 2012-03-21 |
| ATE512674T1 (de) | 2011-07-15 |
| AU2004203682A8 (en) | 2009-09-17 |
| AU2009251223A1 (en) | 2010-01-28 |
| DK1583562T3 (da) | 2011-09-19 |
| EP2260874A1 (en) | 2010-12-15 |
| CN1747747B (zh) | 2012-09-05 |
| WO2004060403A3 (en) | 2004-11-18 |
| CA2516056A1 (en) | 2004-07-22 |
| EP1583562A2 (en) | 2005-10-12 |
| BRPI0406647A (pt) | 2005-12-06 |
| CN1747747A (zh) | 2006-03-15 |
| MXPA05007322A (es) | 2006-02-17 |
| AU2004203682A1 (en) | 2004-07-22 |
| PT1583562E (pt) | 2011-09-19 |
| JP2012031197A (ja) | 2012-02-16 |
| WO2004060403A2 (en) | 2004-07-22 |
| AU2004203682B2 (en) | 2009-10-01 |
| AU2009251223B2 (en) | 2012-02-09 |
| US20060182684A1 (en) | 2006-08-17 |
| JP2006515363A (ja) | 2006-05-25 |
| CY1111844T1 (el) | 2015-10-07 |
| CN102775472A (zh) | 2012-11-14 |
| US9221867B2 (en) | 2015-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2368941T3 (es) | Angiopep-1, compuestos relacionados y utilizaciones correspondientes. | |
| CA2406650C (en) | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | |
| ES2383901T5 (es) | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro | |
| ES2380622T5 (es) | Compuestos de anfetamina resistentes al abuso | |
| Demeule et al. | Identification and design of peptides as a new drug delivery system for the brain | |
| Rousselle et al. | Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy | |
| ES2662848T3 (es) | Composiciones farmacéuticas de suministro en el sitio de enfermedad que comprenden paclitaxel | |
| AU2001266272A1 (en) | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | |
| Meng et al. | A modular ROS-responsive platform co-delivered by 10-hydroxycamptothecin and dexamethasone for cancer treatment | |
| US20020071843A1 (en) | Targeted therapeutic agents | |
| US20040223911A1 (en) | Stabilized therapeutic and imaging agents | |
| Shamay et al. | Inhibition of primary and metastatic tumors in mice by E-selectin-targeted polymer–drug conjugates | |
| Thirumalai et al. | Cancer therapy with iRGD as a tumor-penetrating peptide | |
| Yu et al. | New cell-penetrating peptide (KRP) with multiple physicochemical properties endows doxorubicin with tumor targeting and improves its therapeutic index | |
| US20100098637A1 (en) | Dye-loaded nanoparticle | |
| JP6787882B2 (ja) | 血液脳関門の透過性を高める方法およびその使用 | |
| US20100184955A1 (en) | Anticancer prodrug sensitive to target protease | |
| HK1178909A (en) | Aprotinin and analogs as carriers across the blood-brain barrier | |
| ES2325699B1 (es) | Uso del factor de crecimiento de higado (lgf) como regenerador tisular pleiotropico. | |
| BRPI0822415B1 (pt) | Conjugado de hidroxipolímero modificado, uso de conjugado de hidroxipolímero modificado, composição tendo efeito de matar célula de tumor, e, método para produzir o conjugado de hidroxipolímero modificado | |
| Boddy et al. | RMP-7: potential as an adjuvant to the drug treatment of brain tumours | |
| Liaw | Dendrimer-Mediated Targeted Immunotherapies for the Treatment of Glioblastoma | |
| Gupta et al. | Angiogenesis Treatment with CD13 Targeting Nanomedicines |